TP53 and B-cell non-Hodgkin lymphoma: Furthermore, activated STAT5 was found to cooperate with the loss of function of the p53 tumor suppressor gene to both accelerate disease onset and to skew the large tumor spectrum that normally characterize p53-deficient mice to strongly favor B-cell lymphoma/leukemia [36].